<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391570</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1477</org_study_id>
    <nct_id>NCT03391570</nct_id>
  </id_info>
  <brief_title>Comparing Postoperative Pain Following COX-2 and Prostanoids Expression</brief_title>
  <acronym>COX2RCT</acronym>
  <official_title>A Prospective Randomized Clinical Trial for Comparing Postoperative Pain Following COX-2 and Prostanoids Expression in Women Who Underwent Laparoscopic Surgery for Female Genital Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare postoperative pain following COX-2 and prostanoids
      expression in women who underwent laparoscopic surgery for female genital disease in order to
      evaluate the effect of COX-2 on local inflammation, COX-2 and prostanoids expression followed
      by exposure time to carbon dioxide(CO2) gas, and degree of postoperative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women who underwent laparoscopic surgery for female genital disease, the effect of COX-2
      on local inflammation was assessed by randomization, using the COX-2 inhibitor celecoxib and
      placebo, comparative evaluation of expression of COX-2 and prostanoids by pre/postoperative
      peritoneal biopsy and postoperative pain depending on gas exposure time
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of biomarkers expression according to exposure to CO2 gas</measure>
    <time_frame>Peritoneal biopsy will be done twice (intraoperative, at right after trocar insertion and right before trocar removal, an average of 2-3hours)</time_frame>
    <description>Peritoneal biopsy and real-time polymerase chain reaction(RT-PCR), Immunohistochemistry of Biomarkers (COX-2, PGE2, PGF2, PGI2, TXA2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale(VAS) score</measure>
    <time_frame>every six hours for 48 hours</time_frame>
    <description>Degree of postoperative pain (No pain : 0 / Moderate pain : 5 / Unbearable pain : 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of rescue analgesia</measure>
    <time_frame>From postoperation state to discharge (up to 2 days)</time_frame>
    <description>Frequency of additional pain killer (Tramadol 50mg, Ketorolac 2mg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>From postoperation state to discharge (up to 2 days)</time_frame>
    <description>nausea, vomiting, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From postoperation state to discharge (up to 2 days)</time_frame>
    <description>duration of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Female Genital Disease</condition>
  <arm_group>
    <arm_group_label>COX-2 inhibitor (Celecoxib)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celebrex; COX-2 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo drug (Ramnos)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ramnos; Lactobacillus casei variety rhamnosus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COX-2 inhibitor</intervention_name>
    <description>Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery</description>
    <arm_group_label>COX-2 inhibitor (Celecoxib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery</description>
    <arm_group_label>Placebo drug (Ramnos)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preoperative peritoneal biopsy</intervention_name>
    <description>Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)</description>
    <arm_group_label>COX-2 inhibitor (Celecoxib)</arm_group_label>
    <arm_group_label>Placebo drug (Ramnos)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single-port laparoscopic surgery</intervention_name>
    <description>Single-port laparoscopic surgery with CO2 gas</description>
    <arm_group_label>COX-2 inhibitor (Celecoxib)</arm_group_label>
    <arm_group_label>Placebo drug (Ramnos)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postoperative peritoneal biopsy</intervention_name>
    <description>Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)</description>
    <arm_group_label>COX-2 inhibitor (Celecoxib)</arm_group_label>
    <arm_group_label>Placebo drug (Ramnos)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, Age â‰¥ 20 years

          -  Patients with benign female genital disease who need laparoscopic surgery

          -  Patients with benign disease who can be treated by single port laparoscopy

          -  Patients who signed an approved informed consent

        Exclusion Criteria:

          -  Female, Age &lt; 20 years

          -  Pregnancy

          -  Previous cancer history

          -  Patients who refuse to sign an informed consent

          -  Patients with benign female genital disease combined clinical peritonitis (ex.
             tubo-ovarian abscess, tubo-ovaritis, ruptured endometriosis)

          -  Patients with malignant female genital disease

          -  Patients who got surgery with multi-port laparoscopy

          -  Patients who are contraindicated with COX-2 inhibitors (liver disease, renal disease,
             active peptic ulcer, active gastrointestinal tract bleeding, ischemic heart disease,
             hyperkalemia)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Seung Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Seung Kim, PhD</last_name>
    <phone>82-2-2072-4863</phone>
    <email>bboddi0311@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunji Lee, MD</last_name>
      <phone>82-2-2072-2643</phone>
      <email>bliss8880103@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hee Seung Kim, PhD</last_name>
      <phone>82-2-2072-4863</phone>
      <email>bboddi0311@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hee Seung Kim, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>December 30, 2017</last_update_submitted>
  <last_update_submitted_qc>December 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Seung Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>COX-2 inhibitor</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Prostanoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

